Clinical trials: Pharynx Carcinoma
Squamous Cell Carcinoma of the Head and Neck, Oropharynx
Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
Background: Throat cancer is a common tumor that can occur in people infected with the human papilloma virus (HPV). Most people with this cancer survive more than 5 years with standard chemotherapy drugs plus radiation.
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Oropharynx, Human Papillomavirus Viruses, Drug Therapy
- Trial name
- NCT06223568
- Testing
- Docetaxel, Cisplatin, PRGN-2009
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Oropharyngeal Cancer, Human Papillomavirus
Human Papillomavirus (HPV) Oral Transmission Study in Partners Over Time
This research is being done to understand more about a sexually transmitted virus called Human papillomavirus (HPV) in people with oropharyngeal cancer and their partners.
- Trial name
- HOTSPOT (NCT01342978)
- Where
- 4 sites in United States
- Volunteers
- 242 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer
This phase I trial evaluates the best dose, possible benefits and/or side effects of combination therapy with elimusertib (BAY 1895344), stereotactic body radiation, and pembrolizumab in treating patients with head and neck…
- Conditions
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Cutaneous Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT04576091
- Testing
- Biospecimen Collection, Computed Tomography, Elimusertib
- Where
- 11 sites in United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Oropharynx Cancer, Tonsil Cancer
Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Oropharyngeal Cancer.
The objective of this trial is to study the efficacy of treatment of human papilloma virus (HPV) related oropharyngeal cancer with chemotherapy followed by Transoral Robotic Surgery (TORS) as definitive treatment.
- Conditions
- Oropharynx Cancer, Tonsil Cancer, Throat Cancer, Base of the Tongue Carcinoma
- Trial name
- NECTORS (NCT04277858)
- Testing
- Docetaxel
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Nader Sadeghi
HNSCC, Head and Neck Cancer
Immunological Function After Radiation With Either Proton or Photon Therapy
This is a pilot prospective observational cohort study, comprising patients with head and neck cancer (HNSCC) treated with standard of care definitive (chemo)radiation either with photons or protons.
- Conditions
- HNSCC, Head and Neck Cancer, Oropharynx Cancer, Hypopharynx Cancer
- Trial name
- PRO-IMMUNO (NCT06016699)
- Testing
- blood draws
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- University Medical Center Groningen
Head and Neck Cancer
SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck
RATIONALE: SU5416 may stop the growth of head and neck cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00005647
- Testing
- paclitaxel, semaxanib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Case Comprehensive Cancer Center
Nasopharyngeal Cancinoma (NPC)
Radiotherapy Omitting Prophylactic Neck Irradiation With Neoadjuvant and Adjuvant Toripalimab in Nasopharyngeal Carcinoma
This single-arm, phase 2 trial evaluates the efficacy and safety of de-escalated radiotherapy (restricted to the primary tumor, omitting prophylactic neck irradiation) combined with neoadjuvant and adjuvant toripalimab…
- Trial name
- PUPA (NCT07110558)
- Testing
- Without prophylactic neck irradiation, PD-1 antibody (Toripalimab), Cisplatin
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Study of DC-CIK to Treat NPC
Concurrent of radiotherapy and chemotherapy is the main treatment method for patients with nasopharyngeal carcinoma (NPC). However, Relapse remains the major cause of treatment failure.
- Trial name
- NCT01821495
- Testing
- DC-CIK, Dendritic and Cytokine-induced Killer Cells
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Guangxi Medical University
Locally Advanced Oral Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma
Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma
Neoadjuvant immunochemotherapy (NAIC) has demonstrated promising pathological and survival outcomes in patients with resectable locally advanced oral and oropharyngeal squamous cell carcinoma (LA-OSCC/OPSCC).
- Trial name
- NCT07457099
- Testing
- Observation, Postoperative Radiotherapy, PD-1 Inhibitor Maintenance Therapy
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Zhujiang Hospital
Nasopharyngeal Carcinoma
Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma
The purpose of this study is to explore the efficacy and safety of a combination of GP chemotherapy and tislelizumab in neoadjuvant therapy combined with tislelizumab in adjuvant therapy of locoregionally advanced nasopharyngeal…
- Trial name
- NCT05211232
- Testing
- Tislelizumab
- Where
- 4 sites in China
- Volunteers
- 450 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
The Prognostic Value of Human Papilloma Virus in Nasopharyngeal Carcinoma
It is well established that HPV infection has a casual and is a prognostic factor in several cancer types, including oropharynx. We wish to examine if HPV infection has a prognostic significance in nasopharyngeal carcinoma.
- Trial name
- NCT04014738
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Rambam Health Care Campus
Nasopharyngeal Neoplasms
A Trial of Endostar in Combination With Chemotherapy of DF and Sequential Intensity Modulated Radiation Therapy for Patients With Advanced Nasopharyngeal Carcinoma
Among all the head and neck tumors, nasopharyngeal carcinoma (NPC) has a high tendency of recurrence and metastasis. For the advanced NPC patients, chemoradiotherapy is the main way of treatment.
- Trial name
- NCT02444949
- Testing
- endostar, intensity modulated radiation, cisplatin
- Volunteers
- 75 people
- Sponsor
- China Three Gorges University, Yichang, China
Dysphagia
Multifunctional Nutrition Tube in Dysphagia for Nasopharyngeal Carcinoma
This is a prospective multicenter study with patients with delayed dysphagia after radiotherapy for NPC. Patients enrolled are randomly divided equally into the observation group and the control group.
- Trial name
- NCT06265844
- Testing
- Intermittent Oral-esophageal Tube Feeding, Nasogastric Tube Feeding, comprehensive rehabilitation therapy
- Where
- Hong Kong
- Volunteers
- 80 people
- Sponsor
- Zeng Changhao
Nasopharyngeal Carcinoma
LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA)
Patients have a type of cancer called nasopharyngeal carcinoma (NPC) which has either come back, not gone away or is at high risk for coming back after the best treatment we know for this disease.
- Trial name
- NATELLA (NCT00516087)
- Testing
- Genetically modified CTLs
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Baylor College of Medicine
Nasopharyngeal Neoplasms
Clinical Target Volume Based on Disease Extension Risk Atlas and Computer-aided Delineation in Nasopharyngeal Carcinoma
The purpose of this study is to compare individualized clinical target volume (CTV) based on disease extension risk atlas and computer-aided delineation with traditional CTV in intensity modulated radiotherapy (IMRT) for…
- Trial name
- NCT02627807
- Testing
- IMRT using individualized CTV, IMRT using traditional CTV, Gemcitabine and cisplatin (induction chemotherapy)
- Where
- China
- Volunteers
- 386 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Aspirin Improve Survival of N2-3 Nasopharyngeal Carcinoma Patients
Nasopharyngeal carcinoma (NPC) is one of the most common maligancies of China. In the era of intensity-modulated radiotherapy (IMRT), the 5-year overall survival (OS) has now reached 85.0% or more.
- Trial name
- NCT03290820
- Testing
- Radiotherapy, Concurrent chemotherapy, Aspirin
- Where
- China
- Volunteers
- 184 people
- Sponsor
- Sun Yat-sen University
Hypopharyngeal Squamous Cell Carcinoma
Toripalimab in Combination With Chemotherapy as Induced Chemotherapy for Localized Hypopharyngeal Cancer
60% of hypopharyngeal cancers were locally advanced at the time of diagnosis. The standard treatment was surgery and postoperative radiotherapy.
- Trial name
- NCT04296747
- Testing
- induction chemotherapy, surgery, chemoradiotherapy
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Nasopharyngeal Carcinoma, Radiation Therapy Complication
Atorvastatin in Preventing Nasopharyngeal Carcinoma Patients Receiving Radiotherapy From Carotid Stenosis
Patients with head and neck cancer who underwent irradiation have a higher risk of developing severe carotid stenosis, and eventually develop to transient ischemic attack or stroke.
- Trial name
- NCT02022293
- Testing
- Atorvastatin
- Where
- 6 sites in China
- Volunteers
- 324 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Nasopharyngeal Carcinoma
SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
This is an open label, multi-center, phase I/II study to evaluate the efficacy and safety of SHR-1701 in combination with famitinib in subjects with recurrent/metastatic nasopharyngeal carcinoma(R/M NPC).
- Trial name
- NCT05020925
- Testing
- SHR-1701, Famitinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Nasopharyngeal Carcinoma
Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis
oral administration of Tegio capsules for 12 months for NPC patients with high risk of metastasis (AJCC stage T3-4N2M0 or T1-4N3M0) was tested trying to reduce distant metastasis，safety was also evaluated.
- Trial name
- NCT03904225
- Testing
- Tegafur-Gimeracil-Oteracil
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Zhejiang Cancer Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.